세계의 PEG화 단백질 시장 보고서(2025년)
PEGylated Proteins Global Market Report 2025
상품코드 : 1825858
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

PEG화 단백질 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 12.9%로 27억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 희귀질환에 대한 투자 증가, 바이오의약품 산업의 급성장, 정밀의료의 조정, 생물학적 제제의 바이오시밀러 버전과의 경쟁 심화, 혁신적인 시장진입 전략의 채택 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 디지털 헬스 기술 통합, 차세대 페지화 기술, 정밀 의료를 위한 맞춤형 제제, 병용요법에 대한 집중, 환자 중심 의료 모델로의 전환 등을 들 수 있습니다.

향후 5년간 12.9%의 성장률 전망은 지난번 예측보다 0.8% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 스위스나 중국에서 조달하는 PEG화 시약 및 접합 생물학적 제제의 비용을 상승시키고, 신약의 처방을 지연시키거나 제조 비용을 상승시킴으로써 미국의 바이오의약품 부문을 저해할 것으로 예상됩니다. 또한, 상호 관세와 무역 마찰 및 제한 강화로 인한 세계 경제 및 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

생활습관병의 유병률 증가는 향후 몇 년 동안 PEG화 단백질 시장의 성장을 견인할 것으로 예상됩니다. 생활습관병은 주로 건강에 좋지 않은 식습관, 운동부족, 흡연 등 나쁜 습관이나 생활습관 선택으로 인해 발생하는 건강 상태를 말합니다. 이러한 질병은 신체 활동 감소, 가공식품 위주의 식습관, 스트레스 증가 등의 요인으로 인해 더욱 흔해지고 있습니다. PEG화 단백질은 심혈관질환, 당뇨병, 일부 암 등의 증상에 대한 치료제의 효능, 지속시간, 표적 전달을 개선하여 생활습관병 치료에 사용됩니다. 예를 들어, 2024년 5월 영국 정부 기관인 Office for Health Improvement and Disparities는 2022-2023년 영국 18세 이상 성인의 약 64.0%가 과체중 또는 비만으로 분류되어 2021-2022년의 63.8%보다 약간 증가했다고 보고했습니다. 소폭 증가했다고 보고했습니다. 그 결과, 생활습관병 유병률의 증가가 PEG화 단백질 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

PEGylated proteins are therapeutic proteins covalently bonded to polyethylene glycol (PEG), a process aimed at enhancing their pharmacokinetic properties and reducing immunogenicity, thus improving their therapeutic efficacy. These modified proteins find application in various medical fields, including drug delivery, diagnostics, and targeted therapy, offering prolonged action and potentially improving patient outcomes.

The primary products within the PEGylated proteins market include consumables and services, pegylation kits and reagents, monofunctional linear PEGs, bifunctional PEGs, and others. Consumables and services constitute a broad category encompassing products and services vital for PEGylated protein research and development, including kits, reagents, and various support services. The proteins themselves cover a range of types such as colony-stimulating factors, interferons, erythropoietin, recombinant factor VII, and others, serving diverse applications including cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, gastrointestinal disorders, and more. End users of these products and services include pharmaceutical companies, biotechnology firms, contract research organizations, and academic research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The PEGylated proteins market research report is one of a series of new reports from The Business Research Company that provides PEGylated proteins market statistics, including the PEGylated proteins industry global market size, regional shares, competitors with the PEGylated proteins market share, detailed PEGylated proteins market segments, market trends, and opportunities, and any further data you may need to thrive in the PEGylated proteins industry. These PEGylated proteins market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegylated proteins market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to improved therapeutic efficacy, a growing aging population, demand for long-acting formulations, enhanced drug safety profiles, and expanding applications including targeted drug delivery systems.

The pegylated proteins market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing investment in rare diseases, rapid growth of the biopharmaceutical industry, precision medicine tailoring, increasing competition from biosimilar versions of biologic drugs, and adoption of innovative market access strategies. Major trends in the forecast period include the integration of digital health technologies, next-generation pegylation technologies, customized formulations for precision medicine, a focus on combination therapies, and a shift towards patient-centric healthcare models.

The forecast of 12.9% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. biopharma sector by increasing the cost of PEGylation reagents and conjugated biologic drugs sourced from Switzerland and China, thereby delaying novel drug formulations and elevating manufacturing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of lifestyle diseases is expected to drive the growth of the PEGylated proteins market in the coming years. Lifestyle diseases are health conditions primarily caused by poor habits and lifestyle choices, such as an unhealthy diet, lack of physical activity, and smoking. These diseases are becoming more common due to factors like reduced physical activity, diets rich in processed foods, and heightened stress levels. PEGylated proteins are used in the treatment of lifestyle diseases by improving the effectiveness, duration, and targeted delivery of therapeutic agents for conditions like cardiovascular diseases, diabetes, and some cancers. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that in 2022-2023, approximately 64.0% of adults aged 18 and over in England were classified as overweight or obese, a slight increase from 63.8% in 2021-2022. As a result, the rising prevalence of lifestyle diseases is contributing to the growth of the PEGylated proteins market.

Key players in the PEGylated proteins market are focusing on the development of innovative products such as PEGylation reagents to maintain a competitive edge. PEGylation reagents are chemical compounds that attach polyethylene glycol (PEG) chains to biomolecules, modifying their properties for various biomedical applications. For instance, Creative Enzymes, a US-based supplier of food additives and enzymes, introduced DSPE-PEG-Maleimide in May 2023 for targeted drug delivery. DSPE-PEG-Maleimide is a linear heterobifunctional PEGylation reagent containing DSPE phospholipids and maleimide, serving as a valuable self-assembly reagent for preparing PEGylated liposomes or micelles and providing thiol or cysteine reactive maleimide groups, commonly used in targeted drug delivery.

In February 2022, Merck KGaA, a pharmaceutical company based in Germany, acquired Exelead Inc. for $793 million to bolster its presence in the growing market for mRNA therapeutics. Exelead Inc., a US-based biopharmaceutical company specializing in GMP-certified PEGylation services for use in manufacturing process development, is expected to enhance Merck KGaA's capabilities in this sector.

Major companies operating in the PEGylated proteins market are Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc., Novo Nordisk A/S, Evonik Industries AG, Viatris Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Lonza Group Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Kyowa Kirin Co. Ltd., WuXi Biologics, BioMarin Pharmaceutical Inc., Ligand Pharmaceuticals Incorporated, Zydus Cadila, Enzon Pharmaceuticals Inc.

North America was the largest region in the PEGylated Proteins market in 2024. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the PEGylated proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PEGylated proteins market consists of revenues earned by entities by providing services such as analytical services and contract manufacturing services for PEGylated protein. The market value includes the value of related goods sold by the service provider or included within the service offering. The PEGylated proteins market also includes sales of PEGylated enzymes, PEGylated antibodies, and PEGylated hormones. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PEGylated Proteins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pegylated proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pegylated proteins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pegylated proteins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. PEGylated Proteins Market Characteristics

3. PEGylated Proteins Market Trends And Strategies

4. PEGylated Proteins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global PEGylated Proteins Growth Analysis And Strategic Analysis Framework

6. PEGylated Proteins Market Segmentation

7. PEGylated Proteins Market Regional And Country Analysis

8. Asia-Pacific PEGylated Proteins Market

9. China PEGylated Proteins Market

10. India PEGylated Proteins Market

11. Japan PEGylated Proteins Market

12. Australia PEGylated Proteins Market

13. Indonesia PEGylated Proteins Market

14. South Korea PEGylated Proteins Market

15. Western Europe PEGylated Proteins Market

16. UK PEGylated Proteins Market

17. Germany PEGylated Proteins Market

18. France PEGylated Proteins Market

19. Italy PEGylated Proteins Market

20. Spain PEGylated Proteins Market

21. Eastern Europe PEGylated Proteins Market

22. Russia PEGylated Proteins Market

23. North America PEGylated Proteins Market

24. USA PEGylated Proteins Market

25. Canada PEGylated Proteins Market

26. South America PEGylated Proteins Market

27. Brazil PEGylated Proteins Market

28. Middle East PEGylated Proteins Market

29. Africa PEGylated Proteins Market

30. PEGylated Proteins Market Competitive Landscape And Company Profiles

31. PEGylated Proteins Market Other Major And Innovative Companies

32. Global PEGylated Proteins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PEGylated Proteins Market

34. Recent Developments In The PEGylated Proteins Market

35. PEGylated Proteins Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기